Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
about
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countriesAccess to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 CountriesRare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectivesThirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional AnalysisPharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.Shining a light in the black box of orphan drug pricingA comparative study of orphan drug prices in Europe.Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe.Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe diseaseRare diseases and orphan drugs: Latvian storyOrphan drugs expenditure in the Netherlands in the period 2006-2012.Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.State of rare disease management in Southeast Asia.Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Impact of orphan drugs on Latvian budget.Are payers treating orphan drugs differently?Sustainable rare diseases business and drug access: no time for misconceptions.Systematic review of available evidence on 11 high-priced inpatient orphan drugs.Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement.Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?Budget impact analysis of medicines: updated systematic review and implications.Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change.Orphan drugs for rare diseases: is it time to revisit their special market access status?Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey.Comparison of EQ-5D and SF-6D utilities in Pompe disease.Financial and legislative aspects of drug development of orphan diseases on the European market – a systematic reviewDisease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan's National Health Insurance Research DatabaseBudget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
P2860
Q26748763-2EADCC20-E9A8-4026-A1FD-67AEB2C00E7FQ26785430-9B905AC5-9665-4CC8-AD82-89E9DDA18634Q27005639-836852EE-C567-459E-8327-BFFBB990525CQ28553714-81F778A8-28BA-4C31-AD18-85D1569899EBQ31098648-4F0EC48E-5785-4313-884F-01F43942C2B2Q33602241-59F80FB6-0DE9-459D-A624-F22B68E72A65Q33604660-A91E4ECD-963A-488D-9D79-65D9CB4F88C2Q33604678-7757DF76-2165-41D8-9FD7-F7F06244F56CQ33684105-734D7C30-A571-45BF-A671-D17B8517BA62Q34234365-A6D8F390-AFFA-44E8-A629-986860F4FC77Q34333608-E2E677AB-363D-44E2-9922-2A98E2278635Q35126801-B211DEE6-58DE-4995-9CBC-83B8EF1F8E37Q35835153-580EC0F4-D93C-4B66-A901-0B08AC4CEC43Q36092941-3BA9FB24-CBBF-4988-99B9-70BA4DCAF443Q36639084-C10E748D-C5B9-4310-B581-B35A805D5597Q36895393-0267CAA6-C225-4CF7-A837-17BE0981846FQ36897797-99DA0D70-6403-463C-B547-1C11A5C09F6CQ37075327-1964793F-9543-49AF-87A8-8444C353C1B9Q37116422-A6F3302D-4D39-4F27-BBCC-894CE36898BDQ37380325-83CE22F1-0E19-4393-9035-FB3FBAF31829Q37441285-ABD8666B-FBFA-4667-A2F1-2D89C278626BQ37595752-1447DB06-8316-4698-88EE-04DFD550B5F9Q37692633-3F0C23C0-21C0-4675-B509-4A2BBE8B38A9Q38291431-03E5181E-7C0C-4FB2-B4B7-2FFE63F54DC9Q38753699-5019FEC5-9FD7-4293-B0C5-C23F4EC2F443Q43521909-68244822-F8A8-4602-9024-5BF8DF68CD84Q44697952-693E93AB-9E2D-492C-BCD2-D0662B21D01FQ44871497-996F8AD8-1676-40F4-8C00-A7D475754FF0Q46313513-E02FB1F0-AC96-4CDF-A17D-A757CFCA230CQ48061844-2676150A-5FE2-4717-B4F8-E359883FCA3DQ58261059-0F20EC4B-59E5-4D2A-B5CE-EEE950002D10Q58707408-1EF4C5BE-D5D7-4845-9D41-EE7E334CC175Q58803191-3B4AB088-AA57-42DD-8589-C496755B6788
P2860
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
@en
type
label
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
@en
prefLabel
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
@en
P2093
P2860
P356
P1476
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
@en
P2093
Adam Hutchings
Carina Schey
Tsveta Milanova
P2860
P2888
P356
10.1186/1750-1172-6-62
P577
2011-09-27T00:00:00Z
P5875
P6179
1013884821